Your browser doesn't support javascript.
loading
Prevalence of IGRA-positivity and risk factors for tuberculosis among injecting drug users in Estonia and Latvia.
Rüütel, Kristi; Karnite, Anda; Talu, Ave; Abel-Ollo, Katri; Kirvelaite, Gunta; Kliiman, Kai; Loit, Helle-Mai; Uusküla, Anneli.
Afiliación
  • Rüütel K; National Institute for Health Development, 42 Hiiu Street, Tallinn, Estonia. Electronic address: kristi.ruutel@tai.ee.
  • Karnite A; Department of Public Health and Epidemiology, Riga Stradins University, Kronvalda Boulevard 9, Riga, Latvia.
  • Talu A; University of Tartu, 19 Ravila Street, Tartu, Estonia.
  • Abel-Ollo K; National Institute for Health Development, 42 Hiiu Street, Tallinn, Estonia.
  • Kirvelaite G; Riga Outpatient Department, Stationary "Centre of Tuberculosis and Lung Diseases", Riga Eastern Clinical University Hospital, Nicgales 5, Riga, Latvia.
  • Kliiman K; Lung Clinic, Tartu University Hospital, 167 Riia Street, Tartu, Estonia.
  • Loit HM; National Institute for Health Development, 42 Hiiu Street, Tallinn, Estonia.
  • Uusküla A; University of Tartu, 19 Ravila Street, Tartu, Estonia.
Int J Drug Policy ; 25(1): 175-8, 2014 Jan.
Article en En | MEDLINE | ID: mdl-24210296
ABSTRACT

BACKGROUND:

Illegal drug use and HIV are independent risk factors for tuberculosis (TB) among injecting drug users (IDU). Estonia and Latvia have experienced high rates of TB as well as IDU and HIV outbreaks. There is a lack of knowledge about TB among IDUs in these countries. The purpose of the current study was to estimate the prevalence and risk factors of Mycobacterium tuberculosis (MTB) infection among IDUs in Estonia and Latvia.

METHODS:

Participants for this cross-sectional study were recruited from syringe exchange programmes using respondent-driven sampling. For assessing infection with MTB interferon-gamma release assay (IGRA) was used.

RESULTS:

The study included 375 participants from Estonia and 313 from Latvia. The prevalence of IGRA-positivity among IDUs was 7.7% in Estonia and 25.6% in Latvia. HIV-prevalence was 62% in Estonia and 23% in Latvia. In both countries, IGRA-positivity rates did not differ between HIV-positive and HIV-negative participants. IGRA-positivity was independently associated with a prior diagnosis of TB in Estonia and with imprisonment (ever within a lifetime) and preceding contact with a TB patient in Latvia.

CONCLUSION:

Our findings indicate there is an urgent need for a more vigorous approach in providing IDUs with TB screening services.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Tuberculosis / Seroprevalencia de VIH / Abuso de Sustancias por Vía Intravenosa / Interferón gamma Tipo de estudio: Etiology_studies / Observational_studies / Prevalence_studies / Risk_factors_studies Límite: Adolescent / Adult / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: Int J Drug Policy Asunto de la revista: SAUDE PUBLICA / TRANSTORNOS RELACIONADOS COM SUBSTANCIAS Año: 2014 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Tuberculosis / Seroprevalencia de VIH / Abuso de Sustancias por Vía Intravenosa / Interferón gamma Tipo de estudio: Etiology_studies / Observational_studies / Prevalence_studies / Risk_factors_studies Límite: Adolescent / Adult / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: Int J Drug Policy Asunto de la revista: SAUDE PUBLICA / TRANSTORNOS RELACIONADOS COM SUBSTANCIAS Año: 2014 Tipo del documento: Article